Digitized R&D workflows help cell therapy developers reduce manual data handling and accelerate biologics development.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

Gross SC-islet morphology and size were maintained, yet the fraction of NKX6.1-positive β cells fell substantially, pointing ...

Successfully producing large quantities of biotherapeutics, including monoclonal antibodies and recombinant protein products, depends on robust and reliable cell line development (CLD). Issues that ...

Descriptions of the embryo go back at least to the time of Aristotle, but it has only been since the late 19 th century and early 20 th century that advances in experimental approaches allowed ...

ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to advance VERAXA’s lead BiTAC-TCE program toward IND/CTA-enabling activities ...

A new platform developed by researchers at the University of Texas MD Anderson Cancer Center quickly finds and isolates rare, ...